Researchers at the University of Copenhagen have identified the protein NDRG1 as a potential therapeutic target for cancer, utilizing the antimalarial drug quinacrine to exploit specific cellular vulnerabilities. According to a study published in Science Signaling, high levels of NDRG1 correlate with poor patient survival, and inhibiting this protein creates a synthetic lethal interaction that forces cancer cells to die while potentially sparing healthy tissue.
The Mechanism of Synthetic Lethality in Oncology
The research team, led by Assistant Professor Garik V. Mkrtchyan, utilized the concept of synthetic lethality to uncover new ways to treat malignancy. This approach relies on the biological fact that cancer cells often harbor mutations in DNA damage response pathways, leaving them dependent on remaining repair mechanisms to survive.
By inhibiting a second, necessary gene or protein—in this case, NDRG1—scientists can trigger the death of cancer cells that have already lost other vital repair functions. This is a strategy currently used in the treatment of ovarian, breast, and prostate cancers that feature BRCA mutations, which are targeted by PARP inhibitors.
Did you know?
Quinacrine has been used medically for nearly a century. Originally developed as an antimalarial drug, it was later approved for the treatment of lupus before researchers began investigating its potential in precision oncology.
Identifying Drug Sensitivity Through Robotics
To determine which cancers might respond to this approach, the team employed automated robotics to screen more than 130 different cancer cell lines. The findings, published in Science Signaling, indicated that blood cancers often exhibit high NDRG1 expression and are particularly sensitive to quinacrine.
The study also highlighted colorectal cancer cells as a target, specifically those with mutations in the MLH1 and PARP3 genes. When researchers analyzed patient datasets, they confirmed that patients with high NDRG1 expression combined with the loss of these specific genes showed improved survival rates.
Future Directions for Precision Oncology
While quinacrine shows promise, the research team is already looking toward the next phase of development. Because the drug can cause unwanted side effects, the goal is to create more potent and specific small-molecule inhibitors of NDRG1.
“The next steps will be to develop small molecules that inhibit NDRG1 with greater potency and specificity than quinacrine, thereby minimizing potential off-target effects,” Mkrtchyan stated. The team intends to validate these synthetic lethal interactions in preclinical tumor models to determine if targeting the NDRG1 axis can help overcome treatment resistance in a wider variety of cancer types.
Pro Tip: Biomarkers in Treatment
The study suggests that NDRG1 expression levels could eventually be used as a clinical biomarker. Identifying patients with high NDRG1 expression may help clinicians select those most likely to benefit from therapies that specifically target this DNA damage response pathway.
Frequently Asked Questions
What is synthetic lethality?
Synthetic lethality occurs when the loss of one of two genes allows a cell to survive, but the loss of both genes simultaneously causes the cell to die. Cancer treatments use this to target specific vulnerabilities in tumor cells.
Why is NDRG1 significant in cancer treatment?
According to the University of Copenhagen study, high NDRG1 expression is linked to poor survival outcomes. Inhibiting this protein exploits a vulnerability in the cancer cell’s DNA damage response, offering a potential path for precision therapy.
Is quinacrine currently used to treat cancer?
While quinacrine has shown anticancer activity in laboratory settings, it is not a standard cancer treatment. Researchers are currently using it as a starting point to develop more specific, less toxic drugs that target the same biological pathways.
Are you interested in the latest developments in precision medicine? Subscribe to our newsletter for updates on emerging cancer research and clinical trial breakthroughs.
Related reading
- Injectable Biomaterial for Post-Stroke Tissue Repair
- New Research on Exosomes Offers Shingles Pain Treatments
- CDK4/6 Inhibitors in Breast Cancer: Comparing Survival Outcomes (archynewsy.com)
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)